Which pharmacogenomic tests do we offer? |
DNAdose multi-gene test |
DNAdose is a once off, pharmacogenomic test that identifies gene variants in four major enzyme systems and how these genes metabolise commonly prescribed medications. Put simply, DNAdose identifies how your individual genetic structure will respond to medication so your doctor can prescribe the most suitable medication at the right dosage for your body. For more information visit www.dnadose.com
DNAdose single-gene test |
GenesFX Health also offers testing and detailed reports for the following medications as a single gene test: (As well as the tests listed below the following individual genes are also available for genotyping:CYP2D6, CYP2C9, CYP2C19, TPMT, UGT1A1, VKORC1)
Proton Pump Inhibitors | Warfarin | TPMT |
Approximatelt 30% of the caucasian population may require higher doses of certain proton pump inhibitors to ensure the patient is recieveing optimum response. Learn More | By combining patient clinical characteristics with knowledge of CYP2C9 and VKORC1 genotypes, as much as 60% of the variability in warfarin dose requirements can be explained. Learn More | Thioguanine nucleotides can accumulate in patients who have reduced TPMT activity and who are receiving standard thiopurine doses, which may then lead to severe and possibly fatal myelosuppression. Learn More |
Pain Management | Clopidogrel | Tamoxifen |
| Approximately 10% of the population are poor metabolisers of CPY2D6 enzyme and have a severly compromised ability to convert codeine to morphine, and therefore the desirable analgesic effect is not achieved. Learn More | By establishing the CYP2C19 genotype the clinician can now accurately predict if clopidogrel treatment is likely to be effective in the patient requiring anti-platelet therapy. | Tamoxifen PredictAR identifies common variants in the CYP2D6 gene that are responsible for an individual being a poor metaboliser |